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Purpose: To determine the safety of a surgeon’s initial consecutive intravitreal injections using a 
specific protocol and to review the complications that may be attributed to the   injection procedure.
Design: A retrospective chart review.
Participants: Fifty-nine patients (30 females, 29 males) received intravitreal injections of 
pegaptanib, bevacizumab, or ranibizumab as part of their treatment for neovascular age-related 
macular degeneration. The average patient age was 80 years. Twenty-two patients were diagnosed 
with or suspected of having glaucoma. Each patient received an average of 5.8 injections.
Methods: The charts of 59 patients who received a total of 345 intravitreal injections 
(104 pegaptanib, 74 bevacizumab, 167 ranibizumab) were reviewed. All injections were 
  performed in an office-based setting. Povidone–iodine, topical antibiotics, and eye speculum 
were used as part of the pre injection procedure. Vision and intraocular pressure were evaluated 
immediately following each injection.
Main outcome measures: Incidence of post injection complications, including but not limited 
to endophthalmitis, retinal detachment, traumatic cataract, and vitreous hemorrhage.
Results: There were no cases of endophthalmitis, toxic reactions, traumatic cataracts, retinal 
detachment, or vitreous hemorrhage. There was one case each of lid swelling, transient floaters, 
retinal pigment epithelial tear, corneal edema, and corneal abrasion. There were five cases of 
transient no light perception following pegaptanib injections.
Conclusion: The incidence of serious complications was very low for the intravitreal injections 
given. A surgeon’s initial intravitreal injections may be performed with a very high degree of 
safety using this protocol.
Keywords: intravitreal injection, post injection complications, intraocular disease, age-related 
macular degeneration, bevacizumab, endophthalmitis, pegaptanib, ranibizumab
Intravitreal (IVT) injection is a frequently used method for the therapeutic   management 
of many intraocular diseases, particularly those affecting the posterior segment of 
the eye. Already over the past 5 years, the frequency of IVT injections has increased 
tremendously for both seasoned and newly trained ophthalmologists. In fact, IVT 
injection has become one of the most common medical procedures performed in the 
United States.1 Approximately 1.75 million Americans aged over 50 years are living with 
advanced vision-threatening age-related macular degeneration (AMD), and this   number 
is expected to increase 50% to 2.95 million by 2020.2 Although the   complication rate and 
learning curve of other retinal and ophthalmologic procedures have been   investigated,3–7 
those associated with IVT injections has not. Because of the recent   precipitous increase 
in the frequency of these injections by many surgeons it is   important to know how safe 
these are to our patients. Even experienced surgeons who may have not performed large 
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numbers of these procedures in the past now are doing so. 
It is normal for the newly diagnosed patient with exudative 
AMD to be anxious about having a needle repeatedly placed 
in their eye to deliver medication, and it is helpful for them 
to understand how safe these treatments are.
The Eyetech Phase II study had a 4.8% incidence of 
retinal detachment (RD) and the VISION (VEGF Inhibition 
Study in Ocular Neovascularization) Study Year 1 had a 1.3% 
incidence of endophthalmitis.8,9 Later the PIER (Phase IIIb, 
Multicenter, Randomized, Double-Masked, Sham Injection-
Controlled Study of the Efficacy and Safety of Ranibizumab 
in Subjects with Subfoveal Choroidal Neovascularization 
[CNV] with or without Classic CNV Secondary to AMD) 
study had no cases of endophthalmitis or RDs.10 Other serious 
IVT complications can also include iritis/uveitis, intraocular 
hemorrhage, ocular hypertension, retinal vascular occlusions, 
cataract, and hypotony. Prevention of retinal complications 
is important enough that a vitreoretinal surgical simulator 
has been developed for novice, inexperienced, and trained 
surgeons in order to minimize the incidence of these.11 
This begs the question as to whether a surgeon’s initial IVT 
injections are safe. Although complication rates have been 
reported in clinical trials, these do not shed light on the initial 
complication rates of individual surgeons nor of their learning 
curves. Since most patients who receive these injections have 
neovascular exudative AMD, and the larger published studies 
are for this disease, we believed it was important to examine 
complication rates in this patient group. A highly effective 
treatment for exudative AMD involves the direct injection of 
anti vascular endothelial growth factor (anti-VEGF) into the 
vitreous, which inhibits intraocular angiogenesis. Administer-
ing anti-VEGF directly into the vitreous not only maximizes 
intraocular drug levels, but also minimizes the risk of toxicity 
associated with systemic administration.12 Specifically, the 
anti-VEGF agents pegaptanib sodium (Macugen; Eyetech 
Pharmaceuticals, New York, NY) and ranibizumab (Lucentis; 
Genentech, South San Francisco, CA) have been used suc-
cessfully in the treatment of exudative AMD.8,13 Bevacizumab 
(Avastin; Genentech), another anti-VEGF derived from the 
same parent molecule as ranibizumab, has also been used 
successfully as an IVT injection for the   treatment of exuda-
tive AMD.14
The purpose of this study was to analyze the safety 
of initial consecutive IVT injections and to review the 
  complications that may be attributed to the injection 
  procedure when utilizing a specific protocol. Given the 
variation in complication rates that have been published for 
IVT in different time periods, we also wanted to attempt 
to understand whether complication rates are related to the 
learning curve of an individual surgeon or whether they are 
due to modifications of various methodologies associated 
with the techniques that have evolved.
Method
A retrospective study of a single inexperienced   vitreoretinal 
surgeon’s first 345 IVT injections was performed. All   injections 
were given in the surgeon’s office. Patient charts were reviewed 
to determine if and which   complications occurred. Any com-
plications or serious adverse events were noted in the study, 
including but not limited to   endophthalmitis, RD, traumatic 
cataract, and vitreous   hemorrhage. All IVT   injections involved 
the   administration of anti-VEGF agents for the treatment of 
neovascular AMD in 59 patients (30 females and 29 males). 
The average patient age was 80 years. A total of 27, 33, 
and 33 patients received 104, 74, and 167 IVT injections 
of pegaptanib, bevacizumab, and   ranibizumab respectively. 
Bevacizumab was given as 0.05 mL (1.25 mg) IVT injection, 
with the   frequency   determined as per the patient’s response, 
  ranibizumab as 0.05 mL (0.5 mg) IVT injection every 4 weeks, 
and   pegaptanib as 0.09 mL (0.3 mg) IVT injection every 6 
weeks. Initial   injections used pegaptanib as it was the first 
of the three agents available. When bevacizumab was shown 
to be effective, its use was initiated, and when ranibizumab 
became covered by   insurance, both it and bevacizumab were 
used. Different sized needles were used, including 27, 30, and 
32 gauges, and many patients received more than one type of 
anti-VEGF injection. Pegaptani  b came from the   manufacturer 
with an attached 27G needle which was always used. Both 30G 
and 32G needles were used for bevacizumab and ranibizumab 
to determine whether one was any more comfortable than 
the other to the patient. Vision was evaluated immediately 
following injection. Patients were examined immediately 
post injection and monthly to monitor and treat their disease 
and to detect complications.
The procedure for the IVT administration is described in 
the following section.
IVT injection procedure
All injections were performed in an office-based setting 
following this exact procedure. First, the signed informed 
consent was confirmed; the affected eye was identified, 
labeled with a colored sticker above it, and verified with 
each patient. After the pupil was dilated, the patient was 
reclined. Calming background music is played to reduce 
patient anxiety. Care is taken to make sure that the patient is 
comfortable and is positioned so they can breathe normally Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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and keep their head still. Most patients can fully recline but 
some are uncomfortable and are only reclined as far as their 
comfort permits. If patients are photophobic the room lights 
are kept dimmed until the procedure is carried out. Topical 
anesthesia (proparacaine 0.5%) and an antibiotic (Zymar™) 
were applied to the affected eye. The surrounding eye lashes, 
caruncle, and upper and lower eyelids were swabbed with 
povidone-iodine 10%, followed by the insertion of a lid 
speculum. Using sterile technique, preservative-free 4% 
lidocaine was applied for 30 seconds utilizing a cotton tip 
applicator, followed by two drops of sterile Systane® artificial 
tears to the cornea. This action was repeated 3 times.
During the procedure, if the cornea began to dry, an 
additional drop of Systane was given. Then, using sterile 
technique, one drop of sterile 5% betadine solution was 
placed in conjunctival cul-de-sac, avoiding the cornea, for 
a minimum of 30 seconds and the excess was removed with 
a cotton applicator. The proper injection site was located at 
6–7 o’clock of the right eye or at 5–6 o’clock of the left eye. 
The surgeon donned nonsterile gloves. A sterile caliper was 
inspected to make sure the tips were not bent and the exact 
injection site was located. The patient was given a fixation 
target superonasally with the assists finger or hand. The 
needle was uncapped, and the tip was kept away from the 
mouths of the surgeon, assistant, and patient. In   pseudophakic 
or aphakic patients, the injection site was 3.0–3.5 mm pos-
terior to the limbus, inferotemporally, and the needle was 
directed toward the center of the vitreous cavity to a depth of 
4–6 mm. In phakic patients, the injection site was 3.5–4.0 mm 
posterior to the limbus, inferotemporally, and the needle was 
directed more obliquely half way between the center of the 
vitreous cavity and the direction of the optic nerve, to a depth 
of 4 mm. The surgeon then injected 0.09 mL of pegaptanib 
using a 27 gauge needle, or 0.05 mL of ranibizumab, or 
0.05 mL of bevacizumab at the prepped site using either a 
30 gauge or 32 gauge needle, over 0.5–2.0 seconds. After 
the needle was then immediately withdrawn, the surgeon 
checked for retinal perfusion by indirect ophthalmoscopy and 
ensured that each patient could see light and count fingers. 
An antibiotic (Zymar or Vigamox) was instilled immediately 
post procedure. Intraocular pressure (IOP) was measured 
with a tonometer (Tono-Pen; BioRad, Santa Ana, CA) and 
recorded. In addition, Ciloxan ointment was applied to the 
affected eye, and the eye was patched. Each patient was 
given written post operative instructions and warned of the 
symptoms of RD and endophthalmitis. Each patient was 
also given or prescribed an antibiotic (Zymar or Vigamox) 
to instill at home, 4 times a day for 3 days. Patients were 
followed for the development of complications for 6 months 
after the last injection.
Results
There were no complications of myocardial infarction, 
stroke, endophthalmitis, toxic reactions, traumatic cataracts, 
RD, or vitreous hemorrhage (Table 1). One eye developed 
lid swelling, one eye developed transient floaters, one 
eye exhibited a retinal pigment epithelial (RPE) tear, one 
eye developed corneal edema, and one eye sustained a 
corneal abrasion. Mean preoperative IOP was 13 mmHg. 
All the three IVT injections caused significant initial IOP 
spikes: mean IOP of 38.5 ± 11.56 mmHg in the pegaptanib 
group, 37.75 ± 8.36 mmHg in the ranibizumab group, and 
34.88 ± 10.45 mmHg in the bevacizumab group. There was 
no quantitative rate control, and the rate of injection was 
decided by how likely the surgeon believed the eye or head 
might move, with a faster rate utilized for those who appeared 
less steady. The IOP normalized after about 30 minutes 
post injection in all the patients. This was in concert with our 
previous findings on IOP effects of IVT injections in patients 
with and without glaucoma.15
There was a 4.8% (5 out of 104) incidence per injection 
of transient no light perception (NLP) following pegap-
tanib injections, and all of these patients had immediate 
  post injection IOPs of greater than 55 mmHg, while no 
patients went NLP following bevacizumab or ranibizumab 
injections. Our surgeon performed an average of 5.8 injec-
tions per patient.
Discussion
In this retrospective analysis, the complication rate of one sur-
geon’s initial consecutive IVT injections compares favorably 
with published rates in the major clinical trials of ranibizumab 
Table 1 Complications and adverse events in our study (per 
injection, n = 345)
Complications Number of cases
Lid swelling 1
Vitreous floaters 1
rPe tear 1
Corneal edema 1
Corneal abrasion 1
Transient NLP 5a
Arterial thrombotic events 0
endophthalmitis 0
retinal detachment 0
Traumatic cataract 0
Vitreous hemorrhage 0
Note: aPegaptanib group only.
Abbreviations: rPe, retinal pigment epithelial; NLP, no light perception.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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and pegaptanib (Table 2). No incidence of endophthalmitis 
was recorded among the 345 injections performed in our 
study. Among the ranibizumab clinical trials, the MARINA 
(Minimally Classic/Occult Trial of the Anti-VEGF Antibody 
Ranibizumab in the Treatment of Neovascular AMD) study16 
had a per patient incidence of endophthalmitis of 1.0% 
(5 cases in 477 patients), while no cases of endophthalmitis 
were reported in the PIER study.10 In the MARINA study, four 
of the five cases of   endophthalmitis were culture   negative. 
For pegaptanib, the VISION study reported an incidence rate 
of 1.3% per patient (12 cases in 892 patients).9 The Eyetech 
Phase II study did not specify whether or not they had any 
cases of   endophthalmitis.8 Gragoudas et al attributed many 
of the infections in the VISION study to protocol violations, 
the most common being the failure to use a lid speculum.17 
The antisepsis procedure originally described in the VISION 
study protocols was revised in a protocol amendment after 
approximately 60% of the   injections were administered 
for the 2 years of these studies. The amendment reinforced 
the aseptic nature of the procedure and mandated the use 
of (1) sterile preparation and drape similar to that used 
for routine intraocular surgery and (2) either preinjection 
topical   ophthalmic antibiotic drops for 3 days before the 
injection or a 10-mL povidone–iodine flush immediately 
before injection.
Improvements in sterile procedure apparently reduced the 
incidence of endophthalmitis in Year 2 of the VISION study, 
as none were reported in the second year. It should also be 
noted that the 27-gauge needle size used for pegaptanib is 
larger than that used for ranibizumab and bevacizumab IVT 
injections. The lower incidence of endophthalmitis in our 
study compared with those reported in the VISION study 
is likely related to lessons learned since that trial regarding 
the prevention of endophthalmitis. These include strict atten-
tion to sterile technique, including the use of a lid speculum 
and povidone–iodine, and possibly topical antibiotics both 
before and after injection.18 The use of povidone–iodine 
is able to reduce the number of ocular surface bacteria by 
91%, the likely source of post procedure infection.19 The use 
of topical antibiotics is up to the physician’s discretion, but 
antimicrobial resistance should be considered when selecting 
an appropriate antibiotic.
Some concern has been brought up over the use of 
bevacizumab in IVT injections as being another possible 
source of infection. While pegaptanib and ranibizumab 
are labeled for IVT use, bevacizumab is labeled for use in 
cancer therapy and is currently being used “off-label” for 
the treatment of exudative AMD. Because of its “off-label” 
use, bevacizumab is supplied in much larger volumes than 
those needed for single IVT doses. Thus, hospitals and 
compounding pharmacies must divide the larger volume 
of bevacizumab into smaller units suitable for single-use, 
individual doses. Contaminants could possibly be   introduced 
during the compounding process and compromise the 
  sterility of the aliquoted drug. Although we used bevaci-
zumab prepared by a compounding pharmacy, we did not 
have a higher incidence of endophthalmitis. Our incidence 
of endophthalmitis still compares favorably with the rates 
in clinical trials of ranibizumab and pegaptanib.
No incidence of RD was reported in our study nor in 
the MARINA and PIER studies.10,16 The incidence rate of 
RD was 4.8% (1 case in 21 patients) in the Eyetech study 
and 0.7% (6 cases in 892 patients) in the first year of the 
VISION study.8,9
Table 2 Complications and adverse events secondary to IVT injections performed by one surgeon, compared with ranibizumab and 
pegaptanib clinical trials (incidence per patient)
Complications Our study 
n = 59
Rosenfeld,  
MARINA study16 
n = 477
Regillo, 
PIER study10 
n = 120
Eyetech study,  
Phase II8 
n = 21
D’Amico, VISION  
study, Year 19 
n = 892
D’Amico, VISION   
study, Year 29 
n = 606
Lid swelling 1.7% N/A N/A 14.3% N/A N/A
Vitreous floaters 1.7% N/A N/A 19.0% 33% 24%
rPe tear 1.7% 0.4% 0 N/A N/A N/A
Corneal edema 1.7% N/A N/A N/A 10% 9%
Corneal abrasion 1.7% N/A N/A 14.3% N/A N/A
Transient NLP 8.5% N/A N/A N/A N/A N/A
Arterial thrombotic events 0 3.8% 0 N/A 3% 2%
endophthalmitis 0 1.0% 0 N/A 1.3% 0.6%
retinal detachment 0 0 0 4.8% 0.7% 1.2%
Traumatic cataract 0 0.2% 0 0 0.6% 0.2%
Vitreous hemorrhage 0 0.4% 0 N/A 1.8% 1.8%
Abbreviations: IVT, intravitreal; rPe, retinal pigment epithelial; N/A, not applicable; NLP, no light perception.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Out of six cases of RD reported in the VISION study, 
two subjects had RDs that were exudative/hemorrhagic in 
nature and were attributed to the underlying disease process. 
The other four subjects had RDs with a rhegmatogenous 
component; risk factors included retinoschisis in the study 
eye of one of these subjects, and lattice degeneration in the 
study eye and a history of RD in the fellow eye in a second 
subject. We believe that indirect ophthalmoscopy to examine 
the peripheral retina prior to the IVT injection is necessary 
to help avoid such complications in high-risk patients like 
high myopia with lattice degeneration, history of retinoschsis, 
and any previous history of RD in fellow eye. No cases of 
vitreous hemorrhage or lens damage (traumatic cataract) were 
reported in our study. The incidence of these   complications 
was rare in the MARINA study, with only two cases of 
  vitreous hemorrhage and one case of traumatic cataract being 
reported out of 477 patients.16 No cases of traumatic cataract 
or vitreous hemorrhage were reported in the PIER study.10 
In the first year of the VISION study, the per patient incidence 
of vitreous hemorrhage was 1.8% (16 cases/892 patients).9 
It was determined that the hemorrhage in 7 of the 16 subjects 
was related to underlying choroidal neovascularization, while 
the other nine cases were related to the injection procedure. 
The incidence of traumatic cataract was 0.6% and 0.2% 
in the first and second year, respectively. Many cases of 
traumatic cataract can be attributed to the injection procedure, 
where the needle contacts or penetrates the lens capsule.20 
However, these   complications are rare, both in our study 
and in the clinical trials shown here. We believe measuring 
distance from limbus with a caliper 3.5–4.0 mm posterior 
to the limbus in phakic eyes versus 3.0–3.5 mm posterior 
to the limbus in pseudophakic eyes reduced the incidence 
of iatrogenic cataract formation in our group. Fine-tipped 
calipers can become bent with use, defeating their purpose, 
so they must be inspected.
Other adverse events recorded in our study include one 
case each of lid swelling, RPE tear, corneal edema, corneal 
abrasion, and transient vitreous floaters. The lid swelling 
occurred within one day of the procedure and was due to a 
local reaction to the pre injection surgical preparation. We 
now know that RPE tears are more likely to occur in patients 
with large pigment epithelial detachments who receive 
  anti-VEGF injections, and this was true of our patient who 
developed this within one month of the treatment, but this can 
be part of the natural history of exudative AMD as well.21
Perhaps such patients should receive lower doses of anti-
VEGF drugs, but there is no current evidence to support this. 
The cause of the corneal edema which was evident within 
1 week postoperatively was unclear, but it resolved with time. 
The corneal abrasion is believed to be due to the drying of 
the corneal epithelium due to the patient being unable to 
blink while a lid speculum was in place. Not all clinical trials 
made note of these complications. In the MARINA study, 
two cases of RPE tear (0.4% per patient) were recorded.16 
In the VISION study, the incidence of vitreous floaters was 
more common, occurring in 33% of the study participants.9 
Corneal edema occurred in 10% of the patients in the VISION 
study. The Eyetech study noted lid swelling in 14.3% of their 
patients, vitreous floaters in 19.0%, and corneal abrasion in 
14.3%.8 The occurrences of vitreous floaters in the VISION 
and Eyetech studies were transient in nature and attributed 
to the injection procedure. Our patient noted this within one 
day of the procedure.
We believe that low incidence of corneal edema and 
  corneal abrasion in our study (1.7% and 1.7% versus 
9%–10% and 14.3% respectively) was because of the use of 
  preservative-free, single unit 4% lidocaine and the judicious 
use of artificial tears. After the initial corneal abrasion, we 
learned the importance of avoiding drying of the corneal 
epithelium. The cornea must be kept moist particularly in 
patients with a preexisting abnormal corneal surface such 
as those with dry eyes and those who frequently instill drops 
with preservatives such as glaucoma patients on multiple 
medications.
Five cases in our study noticed transient NLP immediately 
post injection. All five case received pegaptanib, which is a 
larger 0.09 mL volume as compared with 0.05 mL of beva-
cizumab and ranibizumab. We believe that the transient NLP 
in the petaptanib group was due to a volume-mediated IOP 
spike causing transient ischemia. All these patients underwent 
immediate anterior chamber paracentesis, which normalized 
the IOP. Although smaller volumes of anti-VEGF are being 
used now, we thought it may be relevant to discuss this from 
a historical standpoint. Information on short-term IOP trends 
after IVT injections is limited; particularly in patients with 
glaucoma as clinical trials on antivascular endothelial growth 
factor therapies tend to exclude eyes with glaucoma. The 
effect of the IOP spikes on the already compromised optic 
nerve in glaucoma patients is not known. However, caution 
may be prudent in patients with advanced glaucoma, and 
pre-injection paracentesis may be considered in patients 
who have demonstrated significant IOP spikes after previous 
injections, when repeated injections are indicated. We don’t 
currently recommend doing a paracentesis in all patients who 
develop transient NLP as we did in the patients in this study. 
Needle size did not correlate with complications other than Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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the association of the larger needle with the higher IOP and 
transient NLP in the pegaptanib group, but it does not appear 
to be causative. However, we did not use a 27G needle with 
the other medication volumes so we cannot state that with 
certainty. There were no other types of complication associ-
ated with the IOP spikes.
Although a formal analysis was not performed, it did not 
seem as though there was a real difference in comfort level 
between the 30G versus 32G needle, though both were more 
comfortable than the 27G needle.
Although the numbers of patients in the clinical studies 
were in general larger, we believe that the initial 345 injec-
tions performed by a single surgeon provides an excellent 
assessment of the “learning curve” associated with this 
procedure. This is an important issue given the frequency 
of IVT injections, the recent dramatic increase in their fre-
quency, and the potential complications. As our study has 
shown, initial injections can be performed with an excellent 
safety profile even during the initial stage of a physician’s 
experience with IVT injections. The transient cases of NLP 
vision were unrelated to the “learning curve” based on their 
sporadic occurrence.
There are some obvious limitations to this study. This 
is a retrospective investigation of a single surgeon’s IVT 
  injections, without randomized comparisons between alter-
nate techniques or other treating ophthalmologists. Also, 
our study included patients who received IVT for exudative 
AMD only. The surgeon had very limited experience, giving 
less than 10 IVT injections for causes other than AMD that 
were not part of this study. Though these occurred during 
this same time period, they did not affect the conclusions 
of this study and were not associated with complications 
other than the known effect of increased IOP after a Kenalog 
injection.
We learned that IVT is safe to perform when: the 
patient is comfortably positioned so they may remain still; 
proper sterilization techniques are utilized, including 5% 
betadine; calipers are used to measure the exact injection 
site (to avoid iatrogenic cataract formation and retinal 
breaks); those patients with a history of high myopia, 
lattice   degeneration, retinoschisis, or a previous history 
of RD are followed closely; the cornea is kept moist at all 
times with the use of artificial tears; and preservative-free 
lidocaine is utilized   during the injection procedure. Though 
the results of others may vary, we have shown in this study 
that a surgeon’s initial IVT injections with this protocol 
may be performed with a high degree of safety in the office 
setting, and with a very low risk of ocular complications. 
We believe that if our procedure is meticulously followed, 
complications will be reduced and patients will be even 
more accepting of the treatment. Given the precipitous 
increase in the frequency of these injections, this is 
encouraging to all of our patients.
Note
This work was presented in part at the Association for 
Research in Vision and Ophthalmology (ARVO) Annual 
Meeting 2008.
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